Press release 📈 Stocks 🌍 China

Innovent Biologics Expands Phase 3 MarsLight-11 Study for NSCLC Treatment

Innovent Biologics broadens the scope of its Phase 3 MarsLight-11 study, targeting a wider patient population for its IBI363/TAK-928 oncology candidate to strengthen its market position.

📅 September 28, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: 01801.HK ↑ 6/10 (65% confidence).

📊 Affected Assets (1)

01801.HK

Bullish 🤖 65%

📆 Mid-term 🌍 HK · Explicit

Expansion of the Phase 3 MarsLight-11 study to include non-squamous NSCLC patients broadens the potential market for IBI363/TAK-928, supporting a positive outlook for Innovent.

🧭 Full analysis of these assets

🎯 Key Takeaways

Phase 3 MarsLight-11 study now includes non-squamous NSCLC patient cohorts.
Expansion increases the addressable market for the IBI363/TAK-928 drug candidate.
Innovent continues to prioritize oncology as a core pillar of its clinical development strategy.

📝 Executive Summary

Innovent Biologics has announced the expansion of its Phase 3 MarsLight-11 clinical trial to include patients with non-squamous non-small cell lung cancer (NSCLC). This strategic move broadens the potential market reach for the company's IBI363/TAK-928 candidate, signaling a significant step forward in its oncology pipeline development.

❓ FAQ

What is the significance of the MarsLight-11 study expansion?

The expansion allows Innovent to evaluate the efficacy of IBI363/TAK-928 in non-squamous NSCLC patients, potentially broadening the drug's future clinical application and market opportunity.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article